Shopping Cart
Remove All
Your shopping cart is currently empty
Ociperlimab
😃Good
Catalog No. T78324Cas No. 2342597-93-5
Alias WCD-118, WCD118, BGB-A1217, BGBA1217
Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.
Ociperlimab
Ociperlimab
😃Good
Catalog No. T78324Alias WCD-118, WCD118, BGB-A1217, BGBA1217Cas No. 2342597-93-5
Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $742 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.17% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors. |
| Targets&IC50 | TIGIT:0.135 nM (Kd) |
| In vitro | Treatment with Ociperlimab (0-10 μg/mL) increased the secretion of IFN-γ by cytomegalovirus-specific T cells. Ociperlimab (1-1000 ng/mL) activates natural killer cells and monocytes in an FC-dependent manner. Ociperlimab removes TIGIT from the surface of T cells through FC-dependent endocytosis in vitro. [1] |
| In vivo | Ociperlimab (3 and 10 mg/kg; Intrabitoneal injection) in CT26 WT tumor-bearing human TIGIT knockout mice and MC38 tumor-bearing human TIGIT knockout mice showed that Ociperlimab produced anti-tumor effects in an FC-dependent manner. [1] |
| Synonyms | WCD-118, WCD118, BGB-A1217, BGBA1217 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TIGIT/VSIG9/VSTM3 |
| Molecular Weight | 145.12 kDa |
| Cas No. | 2342597-93-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ociperlimab | purchase Ociperlimab | Ociperlimab cost | order Ociperlimab | Ociperlimab in vivo | Ociperlimab in vitro | Ociperlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.